<!DOCTYPE html>
<html>
  <head><title>Andre Esteva Draft</title></head>
  <body>
    <pre>
        '''Andre Esteva''' is an American entrepreneur and artificial intelligence (AI) scientist. He is the founder and CEO of \[\[ArteraAI]], a medical AI company focused on personalizing cancer therapy. ArteraAI's platform, which combines AI interpretation of pathology images with clinical data, has been adopted internationally and integrated into U.S. standard of care guidelines. Esteva has published extensively in the field of medical AI, and his work has been featured in leading journals including ''Nature'' and ''Nature Medicine''. He was named to the 2025 \[\[TIME100 Health]] list and has received additional recognition from outlets such as TIME, Modern Healthcare, and the World Economic Forum.

        \==Education==
        Esteva received dual undergraduate degrees in Electrical Engineering and Pure Mathematics from the University of Texas at Austin, graduating with highest honors. He was awarded the Outstanding Scholar-Leader Award (Engineering Valedictorian) by UT-Austin.<ref>[https://www.ece.utexas.edu/news/ut-ece-student-andre-esteva-receives-outstanding-scholar-leader-award](https://www.ece.utexas.edu/news/ut-ece-student-andre-esteva-receives-outstanding-scholar-leader-award)</ref> He completed his Ph.D. in Artificial Intelligence at \[\[Stanford University]], where he conducted pioneering research in medical AI, including work that appeared on the cover of ''Nature''.<ref>[https://www.nature.com/articles/nature21056](https://www.nature.com/articles/nature21056)</ref>
        
        \==Career==
        \===Early Career===
        Prior to founding ArteraAI, Esteva held research and engineering roles at Salesforce Research (as Head of Medical AI), Google Research, Sandia National Laboratories, and GE Healthcare.
        
        \===ArteraAI===
        Esteva founded \[\[ArteraAI]] in 2021 to develop AI-driven diagnostics for cancer care. In 2023, the company launched with \$90 million in funding across its seed and Series A rounds.<ref>[https://www.businesswire.com/news/home/20230321005241/en/Artera-Launches-with-%2490-Million-in-Funding-to-Personalize-Cancer-Therapy-With-Multimodal-AI](https://www.businesswire.com/news/home/20230321005241/en/Artera-Launches-with-%2490-Million-in-Funding-to-Personalize-Cancer-Therapy-With-Multimodal-AI)</ref> A Series A1 round of \$20 million followed in early 2024.<ref>[https://www.businesswire.com/news/home/20240201133920/en/ArteraAI-Secures-%2420-Million-in-Funding-to-Further-Personalize-Cancer-Therapy-With-Multimodal-AI](https://www.businesswire.com/news/home/20240201133920/en/ArteraAI-Secures-%2420-Million-in-Funding-to-Further-Personalize-Cancer-Therapy-With-Multimodal-AI)</ref>
        
        ArteraAI developed the first-ever \[\[predictive biomarker]] for localized prostate cancer to be included in the \[\[NCCN]] Guidelines, where it is now the only predictive test for therapy personalization in prostate cancer.<ref>[https://www.businesswire.com/news/home/20240304893588/en/ArteraAI-Announced-as-the-First-and-Only-Predictive-Test-for-Therapy-Personalization-in-the-2024-NCCN-Guidelines-for-Prostate-Cancer](https://www.businesswire.com/news/home/20240304893588/en/ArteraAI-Announced-as-the-First-and-Only-Predictive-Test-for-Therapy-Personalization-in-the-2024-NCCN-Guidelines-for-Prostate-Cancer)</ref> The test also received \[\[Medicare]] reimbursement.<ref>[https://www.businesswire.com/news/home/20240103190751/en/ArteraAI-Receives-Medicare-Payment-Rate-for-the-ArteraAI-Prostate-Cancer-Test](https://www.businesswire.com/news/home/20240103190751/en/ArteraAI-Receives-Medicare-Payment-Rate-for-the-ArteraAI-Prostate-Cancer-Test)</ref> A prospective Phase III clinical trial, PROSTATE-IQ, uses ArteraAI’s test to stratify patients for treatment.<ref>[https://www.urotoday.com/conference-highlights/asco-2024/asco-2024-prostate-cancer/152498-asco-2024-randomized-prostate-iq-trial-to-reduce-adt-treatment-burden-for-patients-with-biochemical-recurrence-after-prostatectomy.html](https://www.urotoday.com/conference-highlights/asco-2024/asco-2024-prostate-cancer/152498-asco-2024-randomized-prostate-iq-trial-to-reduce-adt-treatment-burden-for-patients-with-biochemical-recurrence-after-prostatectomy.html)</ref>
        
        The company has expanded internationally, launching in the United Kingdom through a partnership with Diagnexia.<ref>[https://www.diagnexia.com/news/diagnexia-and-artera-partner-to-bring-groundbreaking-ai-prostate-test-to-the-uk](https://www.diagnexia.com/news/diagnexia-and-artera-partner-to-bring-groundbreaking-ai-prostate-test-to-the-uk)</ref> ArteraAI was named a 2024 TIME Best Invention<ref>[https://www.businesswire.com/news/home/20241107591506/en/Arteras-Multimodal-Artificial-Intelligence-Named-Among-TIMEs-2024-Best-Inventions](https://www.businesswire.com/news/home/20241107591506/en/Arteras-Multimodal-Artificial-Intelligence-Named-Among-TIMEs-2024-Best-Inventions)</ref> and selected to join the \[\[World Economic Forum]]'s Global Innovators.<ref>[https://initiatives.weforum.org/innovator-communities/globalinnovators](https://initiatives.weforum.org/innovator-communities/globalinnovators)</ref>
        
        \==Publications==
        Esteva has authored numerous influential works in medical AI, accumulating over 25,000 citations.<ref>[https://scholar.google.com/citations?user=MN8r\_gMAAAAJ\&hl=en](https://scholar.google.com/citations?user=MN8r_gMAAAAJ&hl=en)</ref> His research includes:
        
        * "Dermatologist-level classification of skin cancer with deep neural networks" (''Nature'', 2017) – Cover article demonstrating AI diagnostic parity with clinicians.<ref>[https://www.nature.com/articles/nature21056](https://www.nature.com/articles/nature21056)</ref>
        * "A guide to deep learning in healthcare" (''Nature Medicine'', 2019) – Cover article on the applications of deep learning in medicine.<ref>[https://www.nature.com/articles/s41591-018-0316-z](https://www.nature.com/articles/s41591-018-0316-z)</ref>
        * "Reporting guidelines for clinical trial reports for AI interventions" (''Nature Medicine'', 2020).<ref>[https://www.nature.com/articles/s41591-020-1034-x](https://www.nature.com/articles/s41591-020-1034-x)</ref>
        * "Prostate Cancer Therapy Personalization via Multi-modal Deep Learning" (''NEJM Evidence'', 2024).<ref>[https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300023](https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300023)</ref>
        
        \==Recognition==
        
        * TIME100 Health 2025 honoree.<ref>[https://time.com/collections/time100-health-2025/7279595/andre-esteva/](https://time.com/collections/time100-health-2025/7279595/andre-esteva/)</ref>
        * Modern Healthcare 40 Under 40 (2025).<ref>[https://www.modernhealthcare.com/events/modern-healthcare-2025-40-under-40](https://www.modernhealthcare.com/events/modern-healthcare-2025-40-under-40)</ref>
        * TIME contributor on the use of AI in cancer care.<ref>[https://time.com/6325485/ai-cancer-moonshot/](https://time.com/6325485/ai-cancer-moonshot/)</ref><ref>[https://time.com/6995839/ai-stress-cancer-diagnosis-essay/](https://time.com/6995839/ai-stress-cancer-diagnosis-essay/)</ref>
        
        \==External links==
        
        * \[[https://artera.ai/](https://artera.ai/) ArteraAI official site]
        * \[[https://scholar.google.com/citations?user=MN8r\_gMAAAAJ\&hl=en](https://scholar.google.com/citations?user=MN8r_gMAAAAJ&hl=en) Andre Esteva on Google Scholar]
        * \[[https://www.linkedin.com/in/andre-esteva-phd-ab6b2438/](https://www.linkedin.com/in/andre-esteva-phd-ab6b2438/) Andre Esteva on LinkedIn]
        
        \[\[Category\:American scientists]]
        \[\[Category\:Artificial intelligence researchers]]
        \[\[Category\:Stanford University alumni]]
        \[\[Category\:University of Texas at Austin alumni]]
        \[\[Category\:Living people]]
        \[\[Category:21st-century American businesspeople]]
        
    </pre>
  </body>
</html>

